Overview of management strategies of Juvenile Idiopathic Arthritis

Yasir Ghareeb Ibrahim Alrashdan, Atheer Musaed Aljuhani, Khalid Sukhail G Alshammari, Ghadah fahad sulaiman aloliqi, Rawaby khalid alshammari, Alaa Abdullah Abujabal, Omar mohammad obaid Alshammari, Athir athallah alruwaili, Rashed Sattam Abdulaziz Al-Shammri, Faris Mohammed Wasil Alharbi

Abstract:

Juvenile idiopathic arthritis is a wide definition that describes a clinically heterogeneous group of arthritis's of unknown reason, which onset before 16 years of age. The most important new management methods and diagnosis has been discussed in this review of the biologic medications. We review the most updated studies in the management strategies of Juvenile Idiopathic Arthritis, but we also included some studies which are published from earlier, up to December, 2017. JIA is one of the most common rheumatic illness that impacts kids and is a significant reason for both short- and long-term impairments. Especially, JIA is defined as arthritis of unidentified etiology and its medical diagnosis requires clinical exclusion of other known conditions. Excessive delay in instituting advanced treatment for JIA could result in irretrievable damage to joints and various other body organs and harm skeletal growth. Hence, very early discovery of JIA is important to ensure its immediate treatment and to

prevent long-lasting complications, including the likelihood of disability throughout childhood. The recognition of new biomarkers, together with the advancement of more efficient result measures and the refinement of imaging techniques, might promote the implementation of targeted therapies and individualized therapeutic interventions, with the ultimate objectives of enhancing the remission rates while minimizing disease damages and treatment-related side effects.

Introduction:

Juvenile idiopathic arthritis is not a single illness, yet a term that includes all types of arthritis that start prior to the age of 16 years, linger for greater than 6 weeks, and are of unidentified reason. The term stands for, for that reason, an exemption diagnosis that includes all forms of childhood chronic arthritis of unidentified cause. Various classification requirements have been used to determine discrete clinical subsets that can correspond to various diseases. The International League of Associations for Rheumatology (ILAR) has supplied the most current category [1].The purpose of this classification was to deal with the disadvantage of the previous heterogeneity in nomenclature and criteria between Europe and North America, and to allow recognition of homogeneous groups of kids with chronic arthritis to assist with research study on cause, pathogenesis, epidemiology, end result researches, and therapeutic trials. The term juvenile idiopathic arthritis was taken on as opposed to juvenile chronic arthritis or juvenile rheumatoid arthritis, which were formerly utilized in Europe and North America, respectively. Seven disease categories were acknowledged on the basis of attributes present in the very first 6 months of ailment. The ILAR classification is based upon existing knowledge and stands for an useful

referral for international research study. Nonetheless, the category still needs recognition and consensus, has restrictions innate to any category founded on clinical requirements, and will possibly be changed as brand-new information on pathogenesis appears [2].

Juvenile idiopathic arthritis is a wide definition that describes a clinically heterogeneous group of arthritis's of unknown reason, which onset before 16 years of age. The most important new management methods and diagnosis has been discussed in this review of the biologic medications.

Methodology:

We review the most updated studies in the management strategies of Juvenile Idiopathic Arthritis, but we also included some studies which are published from earlier, up to December, 2017 the Midline (PubMed) and Embase databases were searched for relevant articles to our concern subject, and then evidence was extracted carful from each study, to be able to performed this review as an updated study.

Discussion:

- **Classification**

Over the last couple of decades, several category systems for chronic arthritis in childhood have been suggested [3].The existing system, based on the criteria produced by the Pediatric Task Force of the International League of Associations for Rheumatology (ILAR) [4], presented the unifying regard to JIA and detailed seven disease groups (Table 1) [3], on the basis of the clinical and laboratory features existing in the first 6 months of health problem [5].Although the ILAR category has offered well to integrate the terminology throughout Europe and North America and the criteria utilized to sign up patients in research studies and professional tests, it has recently gone through numerous criticisms [6].Particularly, some concerns have been raised regarding using the number of influenced joints and the visibility of psoriasis as criteria to define uniform condition entities [7].Furthermore, it has been revealed that the existence of antinuclear antibodies (ANA) identifies a homogeneous illness subset throughout numerous ILAR types [8].The reasoning underlying a proposal for a brand-new classification of JIA has been lately talked about [9].

Table 1. International League of Associations for Rheumatology (ILAR) classification criteria for chronic arthritis in childhood [3].

Systemic arthritis
Oligoarthrtitis
Persistent
Extended
Polyarthritis RF-negative
Polyarthritis RF-positive
Psoriatic arthritis
Enthesitis-related arthritis

Undifferentiated arthritis

- **Diagnosis**

Juvenile idiopathic arthritis (JIA) is a medical diagnosis of exclusion that, when presumed, requires a full clinical analysis, consisting of household to personal history and current pathologic events, and details focus on discomfort and morning rigidity. A comprehensive health examination needs to constantly be done to take a look at all body joints at both first assessment and follow-up check outs [10].At the end of the browse through, the physician is asked to give his/her international rating of the general degree of disease activity on an aesthetic analog range (VAS), varying from 0 (no task) to 10 (optimum activity) [11].The differential diagnosis of JIA is vast (Table 2). The recognition of systemic JIA could be difficult as arthritis is commonly absent at onset.

Table 2. Differential diagnosis of systemic juvenile idiopathic arthritis

Infections	Acute rheumatic fever
Septicemia	Connective tissue diseases
Bacterial endocarditis	Systemic lupus erythematosus
Brucellosis	Kawasaki syndrome
Typhoid fever	Systemic vasculitides
Leishmaniosis	Inflammatory bowel disease
Viral infections	Castleman's disease
Malignancy	Sarcoidosis
Leukemia	Autoinflammatory syndromes
Lymphoma	Neuroblastoma

Updates on Outcome Measures and Future Outcomes

The incorporation of patient-reported or parent-reported outcomes (PRCOs), when determining the wellness state of patients with pediatric rheumatic conditions, has become crucial in the last few years [12].These devices could assist the doctor to boost the patient management via the identification of one of the most prominent professional problems and to focus the focus on one

of the most pertinent matters for the patient management. On the other hand, this might boost adherence of the patient to therapy by actively taking part in shared decision-making [12].PCROs in JIA might be examined by different tools, consisting of a VAS for rating a kid's total wellness and intensity of pain, and questionnaires for the evaluation of functional capability and health-related lifestyle (HRQoL) [13].Recently, the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) was produced with this purpose [11], introducing a new technique to medical take care of children with JIA, through quantitative data gathered at each see as a standard procedure in order to lead the physician in monitoring the patient with time [14].

A recent physician-centered end result procedure in JIA is the Juvenile Arthritis Disease Activity Score (JADAS). JADAS is a composite condition activity index that is composed by pooling 4 private measures: doctor's global evaluation of disease task (PGA), moms and dad's/ patient's assessment of kid's health (PPGA), count of joints with energetic arthritis (analyzed in 71, 27, or 10 joints, relying on the variation), and ESR [10].Current research studies have revealed that the ESR could be replaced by the C-reactive healthy protein without modifying the performance of the instrument [15].Furthermore, a three-item variation (clinical JADAS, cJADAS), which excludes the acute phase catalyst, was located to associate closely with the initial device [16] The cutoff values of JADAS that match to the main disease activity states of JIA have been lately developed [13].The care of JIA patients can not be possible without proper and confirmed end result steps, for which more work is required [15].

Imaging

Conventional radiography continues to be the gold requirement for the detection of architectural joint damage and growth and maturation disruptions of bones in JIA patients. Over the last few

years, a good deal of effort has been made to create new radiographic racking up systems or to adjust adult approaches for usage in JIA [17]. Nonetheless, the poor sensitivity of ordinary radiographs in identifying active synovitis and its minimal capacity to disclose abrasive adjustments early in the condition course has elevated passion in alternative imaging methods.

MRI is the only device that has the capacity to at the same time examine all functions of synovial condition and is remarkably suited for the analysis of disease activity in the temporomandibular, hip, sacroiliac, and vertebral joints [18].The major advantage of MRI over conventional radiography is the straight visualization of synovitis, cartilage, and very early erosive lesions. Dynamic contrast-enhanced MRI (DCE-MRI) enables the analysis of the time course of signal changes adhering to gadolinium administration.A peculiar lesion noticeable by MRI is periarticular bone marrow edema. This irregularity represents a key forecaster of erosive joint damages in grownups with arthritis [19], yet its significance is still discussed in JIA, as some research studies have revealed that bone abnormalities on MRI resembling bone marrow edema could be seen in healthy and balanced subjects [20].MRI determines early adjustments in both sacroiliac joints and spinal column, especially in ERA and AS patients, as one of the most sensitive sign of swelling on these sites. This imaging could not be made use of consistently in children, but ought to be always thought about when pain in the back exists, because demo of an earlier involvement of the sacroiliac joints could affect the therapeutic technique.

Ultrasonography has numerous benefits over other imaging modalities, consisting of noninvasiveness, rapidity of efficiency, reasonably affordable, ability to check several joints at once, repeatability, security, and high acceptability among patients. Ultrasonography is well matched for the diagnosis and analysis of synovitis and related irregularities, with color and

power Doppler ultrasonographic techniques being thought about superior to grayscale ultrasonography in determining active illness. However, it is an operator-dependent method and calls for training and a careful interpretation of the irregularities. Lately, age- and sex-related typical criteria in cartilage thickness in tiny and large joints on ultrasonographic pictures have been developed [21].The ability to evaluate joints dynamically, and in genuine time, and to capture bone erosions [22], in addition to its efficiency to assist local injections into joints, ligaments, or various other periarticular structures, are added benefits of this method.

- **Treatment**

The optimum technique to the management of a child with JIA is based upon a multidisciplinary group comprising a pediatric rheumatologist, ophthalmologist, orthopedic cosmetic surgeon, professional nurse, physical therapist, occupational therapist, and psychologist [23].Non-pharmacological and medicinal interventions might aid in the management of JIA patients.

Non-Pharmacological Interventions

A vital aim of the management of JIA is to foster the normal psychosocial and social growth of the youngster and to tackle trouble spots triggered by the disease or its effects on family life [25].Involvement in peer-group activities and regular presence at school must be strongly urged, along with showing off activities, like swimming and biking. Ideal focus on psychosocial concerns, with the aid of a pediatric psychologist, whenever required, could have a favorable influence on the health of the child.

Physical rehabilitation and occupational treatment, with the goal to maintain or recover joint function and placement as high as possible and to attain a regular pattern of wheelchair, are

necessary components of the restorative approach to any patients with JIA [24].Orthotic gadgets can be valuable in selected patients (i.e., those with flexion contractures).

Pharmacological Interventions

Nonsteroidal anti-inflammatory drugs (NSAIDs) have generally been the essential therapy for all forms of JIA. Nonetheless, their usage as monotherapy for greater than 2 months is inhibited if arthritis is still active [26].NSAIDs are not illness modifying, yet merely symptomatic medications. Just a couple of NSAIDs are authorized for usage in youngsters: the most usual are naproxen, ibuprofen, and indomethacin. They are typically better endured by kids compared to adults, and the function of antiacids and proton pump inhibitors to lower gastrointestinal complications in pediatric topics is vague. Experience with cyclooxygenase (COX) -2 inhibitors in youngsters is limited [27].Meloxicam, an inhibitor of both COX-1 and COX-2, has shown to be reliable and safe in a controlled test [27].

Intra-articular corticosteroid (IAC) injections are commonly used in the management of children with JIA, specifically in those with oligoarthritis, to cause quick relief of inflammatory symptoms and for useful renovation as well as to obviate the need for regular systemic treatment. The technique of executing multiple IAC shots is used by some pediatric rheumatologists in children with polyarticular JIA to generate timely remission of synovitis, while all at once launching therapy with disease-modifying antirheumatic drugs (DMARDs) and/or a biologic agent. Triamcinolone hexacetonide (TH) is the medication of choice in JIA. Although there are no recognized guidelines for this method, a lot of rheumatologists will restrict the regularity of reinjections to three times per year. Subcutaneous atrophic skin adjustments at the website of injection, periarticular calcifications, crystal-induced synovitis, and septic arthritis are possible

difficulties of IACs. The potential duty of IAC injections in the hip in triggering avascular necrosis of the femoral head doubts.

Conventional DMARDs

Methotrexate (MTX) continues to be the a lot of favored conventional DMARD in the management of JIA due to the fact that of its effectiveness at achieving illness control and appropriate harmful effects.Its effectiveness was established in a regulated test in 1992 at a dose of 10 mg/m2 each week provided by mouth [28] A succeeding randomized study has revealed that MTX exerts its optimum restorative effect with parenteral management of 15 mg/m2 each week. There was no additional advantage in offering higher doses up to 30 mg/m2 each week [29].MTX can be provided both orally and subcutaneously, with some researches reporting no differences in effectiveness. Nevertheless, there is a boosted bioavailability of the subcutaneous course at higher doses, and other investigators have located boosted efficacy after changing from oral to subcutaneous administration.The best efficiency of MTX has been seen in patients with extensive oligoarthritis. A decline in the rate of radiographic progression has been reported in two tiny unchecked studies. Lately, no advantage in prolonging MTX administration for 12 as opposed to 6 months after the accomplishment of illness remission was seen.Tests to monitor complete blood counts, liver enzymes, and kidney function are suggested throughout MTX therapy, although the optimal frequency of screening is not developed. The supplementation of folic or folinic acid might aid to avoid the incident of liver enzyme irregularities, oral ulcerations, and nausea [30].

Leflunomide could have comparable performance and safety and security as MTX and is a different choice to it in instance of intolerance [31].Nonetheless, experience with this drug in childhood arthritis is still restricted.

Biologic DMARDs

Etanercept, a completely human TNF inhibitor, is the initial biologic agent signed up for use in JIA. Its effectiveness at a dosage of 0.8 mg/kg weekly was shown in a controlled test on 69 patients refractory or intolerant to MTX [32].Long-term expansion research studies of the original trial accomplice and numerous nationwide registries have ultimately verified the continual scientific advantage and appropriate security account of the medication. Etanercept in JIA has been shown to enhance ability and quality of life, development speed and bone standing and decrease the progression of radiographic joint damage.Complete disease calm could be achieved in fifty percent of the patients.

Infliximab, a chimeric TNF-α inhibitor, cannot show a statistically substantial difference in its primary result at 3 months in a placebo-controlled trial [33]. Nevertheless, after 1 year the action to infliximab was equivalent to that observed with etanercept. Paradoxically, regardless of comparable efficacy, patients treated with 3 mg/kg of infliximab experienced a better frequency of severe negative occasions and autoantibodies than those provided 6 mg/kg. Infliximab is not approved for usage in JIA.

The efficiency of adalimumab, a recombinant human anti-TNF agent, was established in a controlled trial including patients who were either MTX naive, resistant, or intolerant [34], with 94% of patients treated with MTX reacting at week 16, versus 74% who did not get concomitant MTX. Lately, adalimumab was discovered to be highly reliable in children and teens with JIA that had actually been previously treated with other biologic agents [35].Adalimumab is registered for use in JIA both in the USA, at a taken care of dose of 20 or 40 mg every 2 weeks for youngsters less than 30 kg or at the very least 30 kg, specifically, and in Europe, at a dosage of 24 mg/m2 (maximum 40 mg) every 2 weeks.

Conclusion:

JIA is one of the most common rheumatic illness that impacts kids and is a significant reason for both short- and long-term impairments. Especially, JIA is defined as arthritis of unidentified etiology and its medical diagnosis requires clinical exclusion of other known conditions. Excessive delay in instituting advanced treatment for JIA could result in irretrievable damage to joints and various other body organs and harm skeletal growth. Hence, very early discovery of JIA is important to ensure its immediate treatment and to prevent long-lasting complications, including the likelihood of disability throughout childhood. The recognition of new biomarkers, together with the advancement of more efficient result measures and the refinement of imaging techniques, might promote the implementation of targeted therapies and individualized therapeutic interventions, with the ultimate objectives of enhancing the remission rates while minimizing disease damages and treatment-related side effects.

Reference:

1. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classifi cation of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 390–92.
2. Martini A. Are the number of joints involved or the presence of psoriasis still useful tools to identify homogeneous disease entities in juvenile idiopathic arthritis? J Rheumatol 2003; 30: 1900–03.
3. Petty RE, Southwood TR, Manners P, et al. International League of Associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–392.
4. Fink CW. Proposal for the development of classification criteria for idiopathic arthritides of childhood. J Rheumatol. 1995;22:1566–1569.
5. Petty RE, Southwood TR, Baum J, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol. 1998;25:1991–1994.
6. Ramsey SE, Bolaria RK, Cabral DA, Malleson PN, Petty RE. Comparison of criteria for the classification of childhood arthritis. J Rheumatol. 2000;27:1283–1286.
7. Martini A. Are the number of joints involved or the presence of psoriasis still useful tools to identify homogeneous disease entities in juvenile idiopathic arthritis? J Rheumatol. 2003;30:1900–1903.

8. Ravelli A, Felici E, Magni-Manzoni S, et al. Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease. Arthritis Rheum. 2005;52:826–832. doi: 10.1002/art.20945.
9. Martini A. It is time to rethink juvenile idiopathic arthritis classification and nomenclature. Ann Rheum Dis. 2012;71:1437–1439. doi: 10.1136/annrheumdis-2012-201388.
10. Ravelli A, Viola S, Ruperto N, Corsi B, Ballardini G, Martini A. Correlation between conventional disease activity measures in juvenile chronic arthritis. Ann Rheum Dis. 1997;56:197–200. doi: 10.1136/ard.56.3.197.
11. Filocamo G, Davì S, Pistorio A, et al. Evaluation of 21-numbered circle and 10-centimeter horizontal line visual analog scales for physician and parent subjective ratings in juvenile idiopathic arthritis. J Rheumatol. 2010;37:1534–1541. doi: 10.3899/jrheum.091474.
12. Luca NJC, Feldman BM. Health outcomes of pediatric rheumatic diseases. Best Pract Res Clin Rheumatol. 2014;28:331–350. doi: 10.1016/j.berh.2014.04.001.
13. Feldman BM, Grundland B, McCullough L, Wright V. Distinction of quality of life, health related quality of life, and health status in children referred for rheumatologic care. J Rheumatol. 2000;27:226–233.
14. Pincus T, Yazici YSC. Quality control of a medical history: improving accuracy with patient participation, supported by a four-page version of the multidimensional health assessment questionnaire (MDHAQ) Rheum Dis Clin North Am. 2009;35:851–860. doi: 10.1016/j.rdc.2009.10.014.
15. Consolaro A, Giancane G, Schiappapietra B, et al. Clinical outcome measures in juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2016;14:23. doi: 10.1186/s12969-016-0085-5.
16. Consolaro A, Negro G, Chiara Gallo M, et al. Defining criteria for disease activity states in nonsystemic juvenile idiopathic arthritis based on a three-variable juvenile arthritis disease activity score. Arthritis Care Res (Hoboken). 2014;66:1703–1709. doi: 10.1002/acr.22393.
17. Van Rossum MAJ, Boers M, Zwinderman AH, et al. Development of a standardized method of assessment of radiographs and radiographic change in juvenile idiopathic arthritis: introduction of the Dijkstra composite score. Arthritis Rheum. 2005;52:2865–2872. doi: 10.1002/art.21247.
18. Cannizzaro E, Schroeder S, Müller LM, Kellenberger CJ, Saurenmann R. Temporomandibular joint involvement in children with juvenile idiopathic arthritis. J Rheumatol. 2011;38:510–515. doi: 10.3899/jrheum.100325.
19. McQueen FM. Bone marrow edema and osteitis in rheumatoid arthritis: the imaging perspective. Arthritis Res Ther. 2012;14:224. doi: 10.1186/ar4035.
20. Müller L, Avenarius D, Damasio B, et al. The paediatric wrist revisited: redefining MR findings in healthy children. Ann Rheum Dis. 2011;70:605–610. doi: 10.1136/ard.2010.135244.

21. Spannow AH, Pfeiffer-Jensen M, Andersen NT, Herlin T, Stenbøg E. Ultrasonographic measurements of joint cartilage thickness in healthy children: age- and sex-related standard reference values. J Rheumatol. 2010;37:2595–2601.
22. Grassi W, Filippucci E, Farina A, Salaffi F, Cervini C. Ultrasonography in the evaluation of bone erosions. Ann Rheum Dis. 2001;60:98–103. doi: 10.1136/ard.60.2.98.
23. Petty RE, Cassidy JT. Textbook of pediatric rheumatology. Philadelphia: Saunders Elsevier; 2011.
24. Häfner R, Truckenbrodt H, Spamer M. Rehabilitation in children with juvenile chronic arthritis. Baillieres Clin Rheumatol. 1998;12:329–361. doi: 10.1016/S0950-3579(98)80022-8.
25. Wallace CA. Current management of juvenile idiopathic arthritis. Best Pract Res Clin Rheumatol. 2006;20:279–300. doi: 10.1016/j.berh.2005.11.008.
26. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken). 2011;63:465–482. doi: 10.1002/acr.20460.
27. Ruperto N, Nikishina I, Pachanov ED, et al. A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results. Arthritis Rheum. 2005;52:563–572. doi: 10.1002/art.20860.
28. Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N Engl J Med. 1992;326:1043–1049. doi: 10.1056/NEJM199204163261602.
29. Ruperto N, Murray KJ, Gerloni V, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum. 2004;50:2191–2201. doi: 10.1002/art.20288.
30. Ravelli A, Migliavacca D, Viola S, Ruperto N, Pistorio A, Martini A. Efficacy of folinic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis. Clin Exp Rheumatol. 1999;17:625–627.
31. Silverman E, Mouy R, Spiegel L, et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med. 2005;352:1655–1666. doi: 10.1056/NEJMoa041810.
32. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med. 2000;342:763–769. doi: 10.1056/NEJM200003163421103.
33. Ruperto N, Lovell DJ, Cuttica R, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56:3096–3106. doi: 10.1002/art.22838.
34. Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359:810–820. doi: 10.1056/NEJMoa0706290.

35. Schmeling H, Minden K, Foeldvari I, Ganser G, Hospach T, Horneff G. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry. Arthritis Rheumatol. 2014;66:2580–2589. doi: 10.1002/art.38741.